Sharps Technology (STSS) Registration Filing summary

Company overview and business model

• Designs, patents, and seeks to commercialize safety syringes and innovative drug delivery devices, with a focus on healthcare worker and patient safety, product performance, and quality.

• Owns four issued U.S. patents and several pending applications, with a product portfolio including Securegard, Sologard, and SafeR platforms.

• Production capacity established, with recent fundraising used to increase capacity, build inventory, and support working capital.

• Engaged in distribution agreements for global reach, including exclusive arrangements with Roncadelle and a major supply agreement with Stericare Solutions.

• Employs 56 full-time staff, primarily in Hungary, and expects to expand as production scales.

Financial performance and metrics

• Has not generated significant revenues from syringe sales to date.

• Entered a five-year supply agreement with Stericare Solutions for 520 million syringes, expected to generate revenues exceeding $50M.

• Forfeited a $1M deposit related to an asset purchase agreement in Q2 2024.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; any proceeds from other offerings are intended for general working capital.